Key Points
- Insider sale: CEO Michael Metzger sold 17,159 shares on Feb. 9 at an average price of $21.03 for $360,853.77, reducing his stake by 3.37% to 491,690 shares (approx. $10.34M).
- Market and sentiment: SNDX trades around $21.32 with a $1.85B market cap, and analysts show a consensus of "Moderate Buy" with an average price target of $37.20, while large institutions like Vanguard have recently increased holdings.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) CFO Keith Goldan sold 3,410 shares of the stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $21.03, for a total transaction of $71,712.30. Following the transaction, the chief financial officer owned 140,429 shares in the company, valued at approximately $2,953,221.87. The trade was a 2.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Syndax Pharmaceuticals Stock Up 0.6%
NASDAQ SNDX opened at $21.32 on Wednesday. The company has a current ratio of 4.64, a quick ratio of 4.42 and a debt-to-equity ratio of 2.78. The company has a market cap of $1.85 billion, a price-to-earnings ratio of -5.91 and a beta of 0.46. The company has a 50 day moving average of $20.77 and a 200-day moving average of $17.23. Syndax Pharmaceuticals, Inc. has a 1-year low of $8.58 and a 1-year high of $22.73.
Analyst Upgrades and Downgrades
Several analysts have recently issued reports on the company. UBS Group increased their target price on Syndax Pharmaceuticals from $35.00 to $38.00 and gave the stock a "buy" rating in a report on Tuesday, November 4th. Barclays boosted their price target on Syndax Pharmaceuticals from $22.00 to $35.00 and gave the company an "overweight" rating in a research note on Monday, November 24th. HC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of Syndax Pharmaceuticals in a research note on Monday, October 27th. Wall Street Zen raised shares of Syndax Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Syndax Pharmaceuticals in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $37.20.
Read Our Latest Analysis on Syndax Pharmaceuticals
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of SNDX. Larson Financial Group LLC grew its holdings in shares of Syndax Pharmaceuticals by 192.2% during the 3rd quarter. Larson Financial Group LLC now owns 2,922 shares of the company's stock valued at $45,000 after purchasing an additional 1,922 shares during the last quarter. Quantbot Technologies LP bought a new position in Syndax Pharmaceuticals in the 3rd quarter valued at approximately $53,000. Lazard Asset Management LLC acquired a new stake in Syndax Pharmaceuticals in the second quarter valued at approximately $66,000. Tower Research Capital LLC TRC grew its stake in shares of Syndax Pharmaceuticals by 103.3% during the second quarter. Tower Research Capital LLC TRC now owns 8,480 shares of the company's stock worth $79,000 after buying an additional 4,308 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Syndax Pharmaceuticals by 26.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,223 shares of the company's stock worth $89,000 after buying an additional 893 shares in the last quarter.
About Syndax Pharmaceuticals
(
Get Free Report)
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax's research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.
The company's lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
